/Charles%20River%20Laboratories%20International%20Inc_%20logo-%20by%20IgorGolovniov%20via%20Shutterstock.jpg)
Charles River Laboratories has underperformed the S&P 500 over the past 52 weeks, yet Wall Street analysts maintain a highly optimistic outlook about the stock’s prospects.
The 5 Most Interesting Analyst Questions From Charles River Laboratories’s Q1 Earnings Call
NeoGenomics and Charles River Laboratories Shares Plummet, What You Need To Know
Partnership showcases a forward- looking collaboration model that highlights advanced testing expertise
Charles River Laboratories International, Inc. (NYSE: CRL) today announced continued momentum in its digital pathology platform, delivering an end-to-end, AI-enabled workflow that significantly accelerates...
Charles River Laboratories International (NYSE:CRL) reported first-quarter 2026 results that management said were in line to slightly ahead of its prior outlook, while reaffirming its full-year organic...
CRL Q1 Deep Dive: Portfolio Restructuring and Cost Initiatives Set Stage for Margin Expansion
Charles River Laboratories (NYSE:CRL) Exceeds Q1 CY2026 Expectations
– Reports First-Quarter Revenue of $995.8 Million, GAAP Loss per Share of $(0.30), and Non-GAAP Earnings per Share of $2.06 – – Reaffirms 2026 Guidance...